TABLE 2.
Antibiotic | Organism(s) | Time to results (h) | Dye | Parameter(s) studied | Reference(s) |
---|---|---|---|---|---|
Amoxicillin | E. coli | 1–2 | PI + FITC | DNA and protein content | 86 |
Ampicillin | E. coli | 1–3 | PI | Morphology, membrane effects | 108 |
E. coli, K. pneumoniae | 1 | Ethidium bromide + mithramycin | Light scattering, morphology, DNA content | 330 | |
E. coli | 0.5 | Oxonol | Light scattering, membrane effects | 200 | |
Azithromycin | E. coli | <1 | Oxonol | Viable cells | 150 |
R. tsutsugamushi | 72 | FITC | Stained bacterial cells | 160 | |
Benzylpenicillin | S. aureus, MRSAa | 2–4 | Oxonol | Membrane effects | 310 |
E. coli | 4 | Mithramycin + ethidium bromide + FITC | Morphology, DNA and protein content | 37 | |
Cefamandole | E. coli | <0.5 | Ethidium bromide | Light scattering, DNA content | 198 |
Cefazoline | E. coli | <0.5 | Ethidium bromide | Light scattering, DNA content | 198 |
Cefotaxime | E. coli | 1–3 | PI | Light scattering, morphology, membrane effects | 108 |
Ceftazidime | E. coli | 0.5–1 | Ethidium bromide + mithramycin | Light scattering, morphology, DNA content | 331 |
Cefuroxime | E. coli | <1 | Oxonol | Viable cells | 150 |
Chloramphenicol | E. coli | <2 | Mithramycin | DNA content | 302 |
E. coli | 1–2 | PI + FITC | DNA and protein content | 86 | |
Ciprofloxacin | E. coli | 1–3 | PI | Light scattering, morphology, membrane effects | 108 |
E. coli | <6 | PI + cyanoditodyl tetrazolium chloride | Membrane effects, viable cells | 201 | |
E. coli | 0.5–1 | Ethidium bromide + mithramycin | Light scattering, morphology, DNA content | 331 | |
E. coli | 1–2 | PI + FITC | DNA and protein content | 86 | |
Mycobacterium spp. | 6–24 | FDA | Viable cells, metabolic status | 36 | |
E. coli | 0.5–1 | Oxonol | Light scattering, membrane effects, viable cells | 150, 200 | |
Clarithromycin | Mycobacterium spp. | 6–24 | FDA | Cell viability, metabolic status | 36 |
Doxycycline | C. trachomatis | 48 | FITC-antibody | Antibody binding | 75 |
R. tsutsugamushi | 72 | FITC | Stained bacterial cells | 160 | |
E. coli | <2 | Mithramycin | DNA content | 302 | |
Erythromycin | C. trachomatis | 48 | FITC-antibody | Antibody binding | 75 |
Mycobacterium spp. | 6–24 | FDA | Cell viability, metabolic status | 36 | |
E. coli | <2 | Mithraymcin | DNA content | 302 | |
Ethambutol | M. tuberculosis | 24 | FDA | Viable cells, metabolic status | 231 |
M. tuberculosis | ≤24 | FDA | Viable cells, metabolic status | 164 | |
Formaldehyde | E. coli | 1 | PI SYTO-13 | Membrane effects, DNA content | 59 |
Gentamicin | E. coli | 1–3 | PI | Light scattering, morphology, membrane effects | 108 |
E. coli | 0.5–1 | Ethidium bromide + mithramycin | Light scattering, morphology, DNA content | 330 | |
E. coli | 0.5 | Oxonol | Light scattering, membrane effects | 200 | |
E. coli | 1 | Acridine orange | Membrane effects, nucleic acid staining | 202 | |
Gramicidin | E. coli | 1 | Propidium iodide + SYTO-13 | Membrane effects, DNA content | 125 |
Isoniazid | Mycobacterium spp. | 24–72 | Auramine | Microencapsulated bacteria colony growth | 283 |
M. tuberculosis | 24 | FDA | Viable cells, metabolic status | 231 | |
M. tuberculosis | ≤24 | FDA | Viable cells, metabolic status | 164 | |
Kanamycin | Mycobacterium spp. | 6–24 | FDA | Viable cells, metabolic status | 36 |
Mecilinam | E. coli | 1–3 | PI | Light scattering, morphology, membrane effects | 108 |
E. coli | 1–2 | PI + FITC | DNA and protein content | 86 | |
Methicillin | S. aureus, MRSA | 2–4 | Oxonol | Membrane effects | 310 |
Moxalactam | E. coli | <0.5 | Ethidium bromide | Light scattering, DNA content | 198 |
Ofloxacin | C. trachomatis | 48 | FITC-antibody | Antibody binding | 75 |
Oxacillin | S. aureus | 2 | DIOC5(3) | Membrane effects | 237 |
Penicillin | S. aureus | 2 | DIOC5(3) | Membrane effects | 237 |
Rifampin | Mycobacterium spp. | 6–24 | FDA | Viable cells, metabolic status | 36 |
M. tuberculosis | ≤24 | FDA | Viable cells, metabolic status | ||
Mycobacterium spp. | 24–72 | Auramine | Microencapsulated bacteria colony growth | 283 | |
M. tuberculosis | 24 | FDA | Viable cells, metabolic status | 231 | |
Streptomycin | M. tuberculosis | 24 | FDA | Viable cells, metabolic status | 231 |
E. coli | <2 | Mithraymcin | DNA content | 302 | |
Surfactants | E. coli | 1 | Rhodamine + SYTO-13, oxonol + SYTO-17 | Membrane effects, DNA content | 59, 125 |
Thrimethoprim | E. coli | 1–2 | PI + FITC | DNA and protein content | 86 |
Tobramycin | Mycobacterium spp. | 6–24 | FDA | Viable cells, metabolic status | 36 |
Vancomycin | S. aureus, MRSA | 2–4 | Oxonol | Membrane effects | 310 |
Enterococcus spp., E. coli | 0.5–2 | Baclight kit (Molecular Probes.) | Live and dead cells | This work |
MRSA, methicillin-resistant S. aureus.